Li Siyu, Huang Liang, Chen Zhe, Zeng Linan, Li Hailong, Diao Sha, Jia Zhi-Jun, Cheng Guo, Yu Qin, Zhang Lingli
Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Evidence-based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China.
Front Pharmacol. 2022 May 18;13:787113. doi: 10.3389/fphar.2022.787113. eCollection 2022.
Drug use safety in children is a global public health problem. The potentially inappropriate prescription screening tools are expected to reduce adverse drug reactions and promote rational drug use. To systematically evaluate children's potentially inappropriate prescription screening tools and validation studies on these tools. We systematically searched six databases PubMed, Embase, Cochrane Library, CNKI, VIP and Wanfang Data. Two reviewers independently selected articles by the eligible criteria and extracted data. Then we evaluated the coverage of diseases or drugs in these tools and the consistency of items between tools. Five children's potentially inappropriate prescription screening tools were identified, most tools were formed by Delphi expert consensus and focused on respiratory system drugs, anti-infective drugs, and gastrointestinal drugs. The coincidence rates of items between the POPI and the POPI Int, the POPI and the POPI United Kingdom, the POPI United Kingdom and the POPI int, and the POPI United Kingdom and the PIPc were 82.0, 55.1, 51.0 and 2.2% respectively, and the KIDs List did not overlap other four tools. Only the POPI tool developed by French experts was comprehensively validated by studies and most tools have not been validated. The development of screening tools for potentially inappropriate prescribing in children is a neglected field and most tools lack studies to validate clinical applicability. More researchers need to form their national potentially inappropriate prescription screening tools for children based on the best available clinical evidence and the actual clinical situation in their countries.
儿童用药安全是一个全球性的公共卫生问题。潜在不适当处方筛查工具有望减少药物不良反应并促进合理用药。为了系统评价儿童潜在不适当处方筛查工具及其验证研究。我们系统检索了六个数据库，即PubMed、Embase、Cochrane图书馆、中国知网、维普资讯和万方数据。两名评价员根据纳入标准独立筛选文章并提取数据。然后我们评估了这些工具中疾病或药物的覆盖范围以及工具之间条目的一致性。共识别出五种儿童潜在不适当处方筛查工具，大多数工具由德尔菲专家共识形成，主要关注呼吸系统药物、抗感染药物和胃肠道药物。POPI与POPI Int、POPI与POPI英国版、POPI英国版与POPI Int以及POPI英国版与PIPc之间条目的符合率分别为82.0%、55.1%、51.0%和2.2%，而KIDs List与其他四种工具没有重叠。只有法国专家开发的POPI工具经过研究全面验证，大多数工具尚未得到验证。儿童潜在不适当处方筛查工具的开发是一个被忽视的领域，大多数工具缺乏验证临床适用性的研究。更多研究人员需要根据现有最佳临床证据和本国实际临床情况，形成本国儿童潜在不适当处方筛查工具。
